Shane Alden Campbell
Known title: SVP, Proprietary SegmentCIK: 0002068522
Associated companies
Transaction History
| WST | ▲ Buy | Option Exercise | 296 | — | 5/12/2026 | View on chart |
| WST | ▼ Sell | Tax Withholding | 84 | $26K | 5/12/2026 | View on chart |
| WST | ▲ Buy | Option Exercise | 474 | — | 5/12/2026 | View on chart |
| WST | ▼ Sell | Tax Withholding | 135 | $42K | 5/12/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
West Pharmaceutical Services noted in analyst upgrade and market rally
West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.
West Pharmaceutical Services noted in analyst upgrade and market rally. West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.